Open Access<p>UBE2N Regulates Paclitaxel Sensitivity of Ovarian Cancer via Fos/P53 Axis</p>
Author(s) -
Qingyi Zhu,
Jieyuan Chen,
Peipei Pan,
Feng Lin,
Zhihui Xu
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s271164
Subject(s) - paclitaxel , ovarian cancer , gene knockdown , cancer research , oncogene , downregulation and upregulation , in vivo , cancer , transcription factor , biology , gene , medicine , cell cycle , genetics
Chemo-resistance is still considered one of the key factors in the mortality of ovarian cancer. In this work, we found that ubiquitin-conjugating enzyme E2 N (UBE2N) is downregulated in paclitaxel-resistant ovarian cancer cells. It suggests UBE2N to be critical in the regulation of paclitaxel sensitivity in ovarian cancer.